Muscle Dysfunction in Patients With Haematological Diseases

Launched by RIGSHOSPITALET, DENMARK · Dec 3, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the condition known as sarcopenia, which is the loss of muscle mass and strength, in patients who have been diagnosed with certain types of blood cancers, including acute myeloid leukemia, acute lymphoblastic leukemia, and lymphoma. Researchers want to understand how common sarcopenia is among these patients and whether it can help predict their health outcomes during treatment.

To be eligible for this trial, participants must be between the ages of 65 and 74 and diagnosed with malignant lymphomas, acute leukemia, or multiple myeloma. Unfortunately, younger individuals under 18, pregnant women, and those with disabilities that prevent them from testing muscle function cannot participate. If you join the study, you can expect to undergo tests that will assess your muscle strength and function, which will help the researchers gather important information about how muscle health affects recovery in blood cancer patients. Your participation could contribute to better understanding and treatment of muscle dysfunction in these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma referred to treatment at the Department of Haematology, Rigshospitalet.
• Exclusion Criteria:
• • Age: \<18
• • Pregnancy
• • Physical or mental disabilities precluding test of muscle function
• • Inability to read and understand Danish.